Status
Conditions
Treatments
About
An investigational study in the control of the user's accommodative state via visual stimuli.
Full description
The EyeQue Corporation (EyeQue) is developing devices to measure refraction that can be used outside of the clinic. The refraction devices require the user to perform a series of tests while looking through it to view a visual display. The current devices do not currently account for accommodation and therefore may present inaccurate results for the younger population where the accommodation effect is quite significant. This study is aimed at enabling future EyeQue refraction measurement products to overcome this issue and provide the required tools to allow for accommodation measurement, correction and control. Control of the user's accommodative state will allow for measurement of near vision as well as far vision based on the refractive measurement.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Spherical correction > +4D or < -5D, astigmatism < -2.5D.
Using anticholinergic medications (including first-generation antihistamines) or other medications known to affect visual acuity within the greater of 3 days or 5 half-lives prior to enrolling in this study
Using an investigational drug or approved therapy for investigational use within the greater of 3 days or 5 half-lives prior to enrolling in this study
Has initiated any new medication in the past 2 weeks that, in the best medical judgment of the investigator, would impact their participation in the study or ability to use EyeQue devices
Reported or observed eye disease or pathology, including but not limited to:
Eye surgery within the last 12 months (including Lasik or lens replacement)
Subject does not have the physical dexterity to properly operate the EyeQue VisionCheck device or the EyeQue app on the smartphone in the investigator's opinion
PD smaller than 50mm or larger than 75mm.
Any self-reported mental illness or condition, including but not limited to: claustrophobia, fear of simulators, nyctophobia.
Any self-reported neurological diseases, including but not limited to: epilepsy, Alzheimer's, nystagmus.
Primary purpose
Allocation
Interventional model
Masking
38 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal